These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 7761095

  • 1. HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model.
    Zhang Y, Yu D, Xia W, Hung MC.
    Oncogene; 1995 May 18; 10(10):1947-54. PubMed ID: 7761095
    [Abstract] [Full Text] [Related]

  • 2. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.
    Chang JY, Xia W, Shao R, Sorgi F, Hortobagyi GN, Huang L, Hung MC.
    Oncogene; 1997 Feb 06; 14(5):561-8. PubMed ID: 9053854
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of intratracheal lung cancer development by systemic delivery of E1A.
    Chang JY, Xia W, Shao R, Hung MC.
    Oncogene; 1996 Oct 03; 13(7):1405-12. PubMed ID: 8875978
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Mutant SV40 large T antigen as a therapeutic agent for HER-2/neu-overexpressing ovarian cancer.
    Xing X, Matin A, Yu D, Xia W, Sorgi F, Huang L, Hung MC.
    Cancer Gene Ther; 1996 Oct 03; 3(3):168-74. PubMed ID: 8725881
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Adenovirus 5 E1a-mediated gene therapy for human ovarian cancer cells in vitro and in vivo.
    Zang RY, Shi DR, Lu HJ, Cai SM, Lu DR, Zhang YJ, Qin HL.
    Int J Gynecol Cancer; 2001 Oct 03; 11(1):18-23. PubMed ID: 11285029
    [Abstract] [Full Text] [Related]

  • 10. [Down regulation of HER2/neu expression by adenovirus E1A and its anti-tumor activity].
    Lu H, Qin H, Zhang Y.
    Zhonghua Zhong Liu Za Zhi; 2000 Sep 03; 22(5):370-3. PubMed ID: 11778270
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Midkine promoter-based conditionally replicative adenovirus for targeting midkine-expressing human bladder cancer model.
    Terao S, Shirakawa T, Kubo S, Bishunu A, Lee SJ, Goda K, Tsukuda M, Hamada K, Tagawa M, Takenaka A, Fujisawa M, Gotoh A.
    Urology; 2007 Nov 03; 70(5):1009-13. PubMed ID: 17919690
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Gene therapy for ovarian cancers by adenovirus-mediated complete antibody gene].
    Guo MG, Jiang MH, Yang Q, Li YM, Cui ZF, Li LF, Wu MC, Qian QJ.
    Zhonghua Yi Xue Za Zhi; 2004 Jul 17; 84(14):1147-51. PubMed ID: 15387973
    [Abstract] [Full Text] [Related]

  • 19. [The efficacy of autocatalytic casapse-3 driven by human telomerase reverse transcriptase promoter on human ovarian carcinoma].
    Song Y, Shen K, Yu JR.
    Zhonghua Yi Xue Za Zhi; 2007 Nov 06; 87(41):2919-24. PubMed ID: 18261307
    [Abstract] [Full Text] [Related]

  • 20. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
    Akbulut H, Zhang L, Tang Y, Deisseroth A.
    Cancer Gene Ther; 2003 May 06; 10(5):388-95. PubMed ID: 12719708
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.